HALLANDALE BEACH, FL–(Marketwired / Asianet-Pakistan – Nov 13, 2013) – AllaChem, LLC announced today a successful completion of phase 1 clinical study with AV4025, a proprietary orally-bioavailable small molecule that blocks HCV genome replication by targeting viral non-structural protein NS5A. A double-blind, placebo-controlled, single ascending oral dose study with AV4025 showed safety and tolerability in […]
The post AllaChem Announces a Successful Completion of Phase 1 Clinical Study With AV4025, a Potent Small Molecule HCV NS5A Inhibitor for the Treatment of Chronic Hepatitis C Infection appeared first on AsiaNet-Pakistan.